Vis enkel innførsel

dc.contributor.authorNieder, Carsten
dc.contributor.authorHintz, Mandy
dc.contributor.authorOehlke, Oliver
dc.contributor.authorBilger, Angelika
dc.contributor.authorGrosu, Anca L.
dc.date.accessioned2018-02-15T10:29:06Z
dc.date.available2018-02-15T10:29:06Z
dc.date.issued2017-06-26
dc.description.abstractBackground:<br>Many patients with brain metastases from non-small cell lung cancer have limited survival, while others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North American database.<br>Patients and methods:<br>This retrospective study included 269 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status, histology, EGFR and ALK alterations was collected. The Lung-molGPA score was calculated as described by Sperduto et al.<br>Results:<br>Median survival was 5.4 months. The score predicted survival in patients with adenocarcinoma histology and those with other types. For example, median survival was 3.0, 6.2, 14.7 and 25.0 months in the 4 different prognostic strata for adenocarcinoma. The corresponding figures were 2.4, 5.5 and 12.5 months in the 3 different prognostic strata for non-adenocarcinoma.<br>Conclusions:<br>These results confirm the validity of the Lung-molGPA in an independent dataset from a different geographical region. However, median survival was shorter in 6 of 7 prognostic strata. Potential explanations include lead time bias and differences in treatment selection, both brain metastases-directed and systemically.en_US
dc.descriptionSource at <a href=http://doi.org/10.1186/s13014-017-0844-6>http://doi.org/10.1186/s13014-017-0844-6</a>en_US
dc.identifier.citationNieder, C., Hintz, M., Oehlke, O., Bilger, A., Grosu, A.L. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers(lung-molGPA). Radiation Oncology. 2017;12:107:1-6en_US
dc.identifier.issn1748-717X
dc.identifier.otherFRIDAID 1484871
dc.identifier.other10.1186/s13014-017-0844-6
dc.identifier.urihttps://hdl.handle.net/10037/12183
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.relation.journalRadiation Oncology
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleValidation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers(lung-molGPA)en_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel